Complete Filing Data
IMPACT BIOMEDICAL INC. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of $15.56 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean IMPACT BIOMEDICAL INC. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income * | -$11.8M | -$24.7M | -$4.3M | -$7.3M |
| Research And Development Expense | $340.0K | $278.0K | $1.7M | $1.2M |
| Selling General And Administrative Expense | $873.0K | $718.0K | $315.0K | $325.0K |
| Operating Income Loss | -$4.3M | -$28.8M | -$4.0M | -$3.4M |
| Interest Expense | $793.0K | $1.1M | $444.0K | $462.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$14.5M | -$24.7M | -$4.4M | -$7.9M |
| Deferred Income Tax Liabilities Net | $688.0K | $3.3M | $3.2M | $3.2M |
| Net Income Loss Attributable To Noncontrolling Interest | -$32.0K | -$62.0K | -$71.0K | |
| Net Income Loss Available To Common Stockholders Basic | -$4.3M | -$7.1M | ||
| Selling And Marketing Expense | $24.0K | $633.0K | $65.0K | |
| Income Loss From Continuing Operations Attributable To Noncontrolling Entity | -$71.0K | -$204.0K | ||
| Other Nonoperating Income Expense | ||||
| Income Tax Expense Benefit | -$2.6M | $33.0K | -$621.0K | |
| Operating Expenses | $28.8M | $4.0M | ||
| Interest Income Expense Nonoperating Net | $13.0K | $13.0K | $13.0K | |
| Revenue From Contract With Customer Excluding Assessed Tax | $32.0K | $50.0K | ||
| Deferred Income Tax Expense Benefit | -$2.6M | $33.0K | -$621.0K | |
| Cost Of Goods And Services Sold | $424.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$1.5M | -$14.3M | -$1.3M | $4.2M | -$889.0K | -$962.0K | -$1.2M | -$1.1M | -$849.0K | -$2.2M | -$799.0K |
| Research And Development Expense | $52.0K | $75.0K | $103.0K | $82.0K | $121.0K | $183.0K | $357.0K | $266.0K | $179.0K | $330.0K | $206.0K |
| Selling General And Administrative Expense | $261.0K | $246.0K | $248.0K | $132.0K | $145.0K | $148.0K | $101.0K | $41.0K | $40.0K | $90.0K | $58.0K |
| Operating Income Loss | -$948.0K | -$1.2M | -$1.0M | -$1.1M | -$626.0K | -$771.0K | -$1.1M | -$1.0M | -$803.0K | -$889.0K | -$750.0K |
| Interest Expense | $262.0K | $260.0K | $271.0K | $305.0K | $261.0K | $230.0K | $102.0K | $116.0K | $101.0K | $92.0K | $139.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$1.5M | -$14.4M | -$1.3M | $4.2M | -$884.0K | -$998.0K | -$1.2M | -$1.1M | -$849.0K | -$978.0K | -$799.0K |
| Deferred Income Tax Liabilities Net | $3.3M | $3.3M | $3.3M | $3.2M | $3.2M | $3.2M | $3.2M | $3.2M | |||
| Net Income Loss Attributable To Noncontrolling Interest | -$5.0K | -$6.0K | -$11.0K | -$6.0K | $5.0K | -$36.0K | -$15.0K | -$19.0K | |||
| Net Income Loss Available To Common Stockholders Basic | $4.2M | -$889.0K | -$962.0K | -$1.2M | -$1.1M | -$657.0K | -$2.2M | -$732.0K | |||
| Selling And Marketing Expense | $2.0K | $1.0K | $19.0K | $461.0K | $18.0K | $8.0K | $17.0K | $10.0K | $17.0K | ||
| Income Loss From Continuing Operations Attributable To Noncontrolling Entity | -$36.0K | -$15.0K | -$19.0K | -$192.0K | -$67.0K | -$67.0K | |||||
| Other Nonoperating Income Expense | $52.0K | ||||||||||
| Income Tax Expense Benefit | $1.3M | ||||||||||
| Operating Expenses | $1.0M | $1.1M | $626.0K | $771.0K | $1.1M | $1.0M | $803.0K | ||||
| Interest Income Expense Nonoperating Net | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | ||||
| Revenue From Contract With Customer Excluding Assessed Tax | $18.0K | $7.0K | $50.0K | ||||||||
| Deferred Income Tax Expense Benefit | |||||||||||
| Cost Of Goods And Services Sold | $1.0K | $11.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity * | $12.6M | $4.3M | $25.2M | $29.6M | $39.9M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $3.0K | $2.0M | $1.0K | $2.0K | $46.0K |
| Cash And Cash Equivalents At Carrying Value | $3.0K | $2.0M | $1.0K | $2.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$2.0M | $2.0M | -$1.0K | -$44.0K | |
| Retained Earnings Accumulated Deficit | -$49.5M | -$37.7M | -$13.0M | -$8.6M | |
| Other Intangible Assets Net | $17.0M | $17.8M | $18.9M | $20.0M | |
| Notes And Loans Receivable Net Current | $198.0K | $184.0K | $203.0K | $16.0K | |
| Minority Interest | $2.9M | $3.0M | $3.0M | $3.1M | |
| Liabilities Current | $1.2M | $9.8M | $13.1M | $10.6M | |
| Liabilities And Stockholders Equity | $17.4M | $20.3M | $44.6M | $46.5M | |
| Common Stock Value | $105.0K | $11.0K | $10.0K | $70.0K | |
| Assets Current | $411.0K | $2.4M | $332.0K | $122.0K | |
| Assets | $17.4M | $20.3M | $44.6M | $46.5M | |
| Accounts Payable Current | $347.0K | $314.0K | $832.0K | $539.0K | |
| Goodwill | $25.1M | $25.1M | |||
| Accrued Liabilities Current | $194.0K | $194.0K | $230.0K | $63.0K | |
| Notes Payable Current | $8.9M | $12.1M | $10.0M | ||
| Liabilities | $1.9M | $13.1M | $16.4M | $13.8M | |
| Property Plant And Equipment Net | $17.0K | $287.0K | $276.0K | ||
| Prepaid Expense And Other Assets Current | $142.0K | $265.0K | $104.0K | ||
| Notes And Loans Receivable Net Noncurrent | $17.0K | $190.0K | |||
| Other Long Term Investments | $782.0K | ||||
| Preferred Stock Value | $60.0K | $60.0K | |||
| Preferred Stock Liquidation Preference | $0.00 | $0.00 | $0.00 | ||
| Preferred Stock Liquidation Preference Value | $0.00 | $60.50B | $60.0K | ||
| Additional Paid In Capital Common Stock | $38.1M | $38.1M | |||
| Accounts Receivable Net Current | $5.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | -$11.8M | -$10.3M | $3.8M | $31.3M | $23.4M | $24.3M | $26.5M | $27.6M | $31.8M | $36.0M | $38.4M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $12.0K | $624.0K | $1.3M | $2.7M | $2.0K | $2.0K | $201.0K | $3.0K | $1.0K | $101.0K | $131.0K | |
| Cash And Cash Equivalents At Carrying Value | $12.0K | $624.0K | $1.3M | $2.7M | $2.0K | $2.0K | $201.0K | $3.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$681.0K | $1.0K | -$1.0K | |||||||||
| Retained Earnings Accumulated Deficit | -$54.8M | -$53.3M | -$38.9M | -$10.6M | -$14.8M | -$13.9M | -$11.7M | -$10.6M | ||||
| Other Intangible Assets Net | $17.3M | $17.6M | $17.9M | $18.1M | $18.4M | $18.6M | $19.2M | $19.5M | ||||
| Notes And Loans Receivable Net Current | $199.0K | $200.0K | $200.0K | $142.0K | $135.0K | $203.0K | $204.0K | $204.0K | ||||
| Minority Interest | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $3.1M | $3.1M | ||||
| Liabilities Current | $23.8M | $23.2M | $10.0M | $1.1M | $14.5M | $13.9M | $12.3M | $12.1M | ||||
| Liabilities And Stockholders Equity | $18.2M | $19.1M | $20.1M | $46.7M | $44.1M | $44.4M | $45.1M | $46.0M | ||||
| Common Stock Value | $12.0K | $12.0K | $12.0K | $11.0K | $10.0K | $10.0K | $70.0K | $125.0K | ||||
| Assets Current | $917.0K | $1.5M | $2.2M | $3.2M | $307.0K | $335.0K | $501.0K | $348.0K | ||||
| Assets | $18.2M | $19.1M | $20.1M | $46.7M | $44.1M | $44.4M | $45.1M | $46.0M | ||||
| Accounts Payable Current | $576.0K | $554.0K | $615.0K | $1.0M | $986.0K | $1.0M | $476.0K | $301.0K | ||||
| Goodwill | $25.1M | $25.1M | $25.1M | $25.1M | ||||||||
| Accrued Liabilities Current | $336.0K | $266.0K | $217.0K | $102.0K | $61.0K | $47.0K | $6.0K | |||||
| Notes Payable Current | $22.9M | $22.4M | $9.1M | $35.0K | $13.5M | $12.8M | $11.8M | $11.8M | ||||
| Liabilities | $27.1M | $26.4M | $13.2M | $12.3M | $15.5M | $15.3M | ||||||
| Property Plant And Equipment Net | $13.0K | $14.0K | $16.0K | $282.0K | $284.0K | $285.0K | $289.0K | $290.0K | ||||
| Prepaid Expense And Other Assets Current | $206.0K | $171.0K | $172.0K | $365.0K | $42.0K | $2.0K | $96.0K | $47.0K | ||||
| Notes And Loans Receivable Net Noncurrent | $59.0K | $67.0K | ||||||||||
| Other Long Term Investments | $782.0K | |||||||||||
| Preferred Stock Value | $60.0K | $60.0K | $60.0K | $60.0K | $60.0K | $60.0K | ||||||
| Preferred Stock Liquidation Preference | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Preferred Stock Liquidation Preference Value | $60.5M | $60.0K | $60.0K | $60.0K | ||||||||
| Additional Paid In Capital Common Stock | $38.1M | $38.1M | ||||||||||
| Accounts Receivable Net Current | $15.0K | $4.0K | $128.0K | $128.0K | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$1.9M | -$2.9M | -$2.9M | -$2.2M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$126.0K | $265.0K | -$104.0K | $60.0K |
| Increase Decrease In Accrued Liabilities | -$2.0K | -$35.0K | $167.0K | $57.0K |
| Increase Decrease In Accounts Payable | $470.0K | -$436.0K | $293.0K | $424.0K |
| Net Cash Provided By Used In Investing Activities | $3.0K | $2.0K | -$15.0K | -$349.0K |
| Net Cash Provided By Used In Financing Activities | -$109.0K | $4.9M | $2.9M | $2.5M |
| Payments For Proceeds From Note Receivable Investments | -$3.0K | $8.0K | ||
| Proceeds From Related Party Debt | $184.0K | $2.9M | $2.5M | |
| Depreciation Depletion And Amortization | $1.1M | $1.1M | $1.1M | $1.1M |
| Payments For Proceeds From Productive Assets | $18.0K | $276.0K | ||
| Increase Decrease In Accounts Receivable | $1.0K | -$128.0K | ||
| Proceeds From Sale Of Notes Receivable | $3.0K | $2.0K | $3.0K | |
| Share Based Compensation | $13.0K | $19.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$682.0K | -$482.0K | -$1.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$97.0K | $2.0K | $79.0K |
| Increase Decrease In Accrued Liabilities | $12.0K | -$183.0K | -$13.0K |
| Increase Decrease In Accounts Payable | -$98.0K | $191.0K | -$353.0K |
| Net Cash Provided By Used In Investing Activities | $1.0K | -$4.0K | |
| Net Cash Provided By Used In Financing Activities | $483.0K | $1.0M | |
| Payments For Proceeds From Note Receivable Investments | -$1.0K | ||
| Proceeds From Related Party Debt | |||
| Depreciation Depletion And Amortization | $283.0K | $280.0K | $280.0K |
| Payments For Proceeds From Productive Assets | $5.0K | ||
| Increase Decrease In Accounts Receivable | |||
| Proceeds From Sale Of Notes Receivable | $1.0K | ||
| Share Based Compensation | $2.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 31.6M | 10.8M | 60.2M | 70.5M |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 31.6M | 10.8M | 60.2M | 70.5M |
| Earnings Per Share Basic | $-0.38 | $-2.30 | $-0.07 | $-0.10 |
| Common Stock Shares Outstanding | 104.6M | 11.5M | 10.0M | 70.5M |
| Common Stock Shares Issued | 104.6M | 11.5M | 10.0M | 70.5M |
| Common Stock Shares Authorized | 4.00B | 4.00B | 4.00B | 4.00B |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings Per Share Diluted | $-0.38 | $-2.30 | $-0.07 | $-0.10 |
| Preferred Stock Shares Outstanding | 0.00 | 60.5M | 60.5M | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 60.5M | 60.5M | 0.00 |
| Preferred Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 12.2M | 12.2M | 12.1M | 11.5M | 10.0M | 10.0M | 70.5M | 70.5M | 70.5M | 70.5M | 3.88B |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 12.2M | 12.2M | 12.1M | 72.0M | 10.0M | 10.0M | 70.5M | 70.5M | 70.5M | 70.5M | 3.88B |
| Earnings Per Share Basic | $-0.12 | $-1.18 | $-0.11 | $0.37 | $-0.09 | $-0.10 | $-0.02 | $-0.02 | $-0.01 | $-0.03 | $0.00 |
| Common Stock Shares Outstanding | 12.2M | 12.2M | 12.1M | 11.5M | 10.0M | 10.0M | 70.5M | 3.88B | |||
| Common Stock Shares Issued | 12.2M | 12.2M | 12.1M | 11.5M | 10.0M | 10.0M | 70.5M | 3.88B | |||
| Common Stock Shares Authorized | 4.00B | 4.00B | 4.00B | 4.00B | 4.00B | 4.00B | 4.00B | 4.00B | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Earnings Per Share Diluted | $-0.12 | $-1.18 | $-0.11 | $0.06 | $-0.09 | $-0.10 | $-0.02 | $-0.02 | $-0.01 | $-0.03 | $0.00 |
| Preferred Stock Shares Outstanding | 60.5M | 60.5M | 60.5M | 60.5M | 60.5M | 60.5M | |||||
| Preferred Stock Shares Issued | 60.5M | 60.5M | 60.5M | 60.5M | 60.5M | 60.5M | |||||
| Preferred Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | |||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Depreciation And Amortization | $1.1M | $1.1M | $1.1M | $1.1M |
| Professional Fees | $1.0M | $446.0K | $724.0K | $722.0K |
| Investment Income Interest | $13.0K | $24.0K | ||
| Other General Expense | $184.0K | $68.0K | ||
| Costs And Expenses | $4.0M | $3.5M | ||
| Additional Paid In Capital | $62.0M | $41.9M | $38.1M | |
| Other Expenses | $417.0K | $171.0K | $119.0K | |
| Rent And Utilities | $74.0K | $32.0K | ||
| Operating Costs And Expenses | $4.3M | $28.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation And Amortization | $288.0K | $288.0K | $283.0K | $281.0K | $279.0K | $280.0K | $280.0K | $280.0K | $280.0K | $279.0K | $278.0K |
| Professional Fees | $234.0K | $411.0K | $223.0K | $122.0K | $46.0K | $145.0K | $317.0K | $407.0K | $280.0K | $183.0K | $229.0K |
| Investment Income Interest | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $90.0K | ||||
| Other General Expense | $23.0K | $14.0K | $7.0K | $29.0K | |||||||
| Costs And Expenses | $1.1M | $1.0M | $889.0K | $800.0K | |||||||
| Additional Paid In Capital | $42.9M | $42.9M | $42.7M | $41.8M | $38.1M | $38.1M | |||||
| Other Expenses | $109.0K | $110.0K | $115.0K | $45.0K | $12.0K | $3.0K | $6.0K | $4.0K | $7.0K | ||
| Rent And Utilities | $19.0K | $18.0K | $19.0K | $4.0K | $5.0K | $4.0K | |||||
| Operating Costs And Expenses | $966.0K | $1.2M | $1.1M | $626.0K |
Most recent annual filing with the SEC: March 11, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.